Dr. Yongchang Zhang 张永昌
Chief Physician, Lecturer
Medical Oncology (III), Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precision diagnosis and treatment of lung cancer and gastrointestinal malignancies, including early screening, genetic report interpretation, management of recurrence and drug resistance, and adverse event management.
Dr. Zhang is a Chief Physician, Professor, and Doctoral Supervisor at Hunan Cancer Hospital, serving as Director of the Early Clinical Research Center. Recognized as a National Excellent Young Scholar and recipient of the Hunan Bethune Medal, Dr. Zhang leads the Molecular Tumor Multidisciplinary Expert Group and specializes in precision care for complex drug-resistant cases.
Professional roles
- Member, Committee on Precision Cancer Therapy, China Anti-Cancer Association
- Member, Committee on Respiratory Oncology, China Anti-Cancer Association
- Young Member, Chinese Society of Clinical Oncology (CSCO)
- Editor, Annals of Translational Medicine
Name order: in Chinese the family name comes first (Zhang Yongchang). Papers usually list the name as Yongchang Zhang or Zhang Y.
Selected publications
164 papers on PubMed matched by name and affiliation; 65 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Rep Med, 2026 (senior author): Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial. PubMed 42486095
- Cell Rep Med, 2026 (senior author): High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial. PubMed 42379171
- Nat Med, 2026 (senior author): Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. PubMed 42343117
- Chin Med J Pulm Crit Care Med, 2026 (senior author): Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges. PubMed 42396194
- Nat Med, 2026 (senior author): Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. PubMed 41629425
- Innovation (Camb), 2026 (first author): International guidelines on the diagnosis and treatment of NUT carcinoma. PubMed 41737331
- iScience, 2025 (senior author): A translational study on the survival and molecular mechanism of PD-L1 expression in EGFR-mutant NSCLC treated with osimertinib. PubMed 41446744
- Cancer, 2025 (senior author): Overall survival according to time-of-day of immunochemotherapy for extensive-stage small cell lung cancer. PubMed 41355404
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion